SCHEMBL18585144

SCHEMBL18585144

Fc1ccc(OC(F)F)cc1CBr

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MTNR1B P49286 1/20 0.40
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ ALOX15 P16050 1/20 0.36
▸ GFER P55789 1/20 0.36
▸ ADAM17 P78536 1/20 0.36
▸ RORC P51449 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.34
▸ DRD1 P21728 1/20 0.33
▸ MEP1B Q16820 1/20 0.33
▸ FFAR4 Q5NUL3 3/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ PTGER4 P35408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287536 0.85 GPR6 (0.36) PPARGPPARAALOX15GFERADAM17
SCHEMBL16400189 0.81 ALOX15 (0.40) PPARGPPARAALOX15GFERADAM17
SCHEMBL20256607 0.81 SLC6A4 (0.38) MTNR1BPPARGPPARAALOX15GFER
SCHEMBL4680033 0.81 MRGPRX4 (0.40) MTNR1BPPARGPPARAALOX15GFER
SCHEMBL12474356 0.81 PPARG (0.37) MTNR1BPPARGPPARAALOX15GFER
SCHEMBL24587311 0.81 PPARG (0.40) MTNR1BPPARGPPARAALOX15GFER
SCHEMBL1094566 0.80 KCNJ5 (0.42) PPARGPPARAALOX15GFERADAM17
SCHEMBL18216618 0.79 P2RX7 (0.40) MTNR1BPPARGPPARARORCMRGPRX4
SCHEMBL24587369 0.79 PPARG (0.40) MTNR1BPPARGPPARA
SCHEMBL10978751 0.78 GPR3 (0.42) RORCFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10316035-B2 Triazolopyridine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2019-06-11 — — US disclosed
US-20180244671-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MEYERS SQUIBB COMPANY (US) 2018-08-30 — — US disclosed
WO-2017040450-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316035-B2 Triazolopyridine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 MTNR1B 470/4885PPARG 857/4885PPARA 1650/4885
US-20180244671-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 MTNR1B 470/4885PPARG 857/4885PPARA 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback